Our Technology Platform
Enabling Robust CAR Therapies
Simurx’s CTSR platform offers a unique modular system; it can be combined with essentially any CAR construct to produce new product candidates each time. It can be employed with different immune cell types in the context of both autologous and allogeneic immune therapies to provide products for a broad range of solid tumors.
The CTSR platform was developed by Simurx physician scientists, leveraging decades of experience across a broad spectrum of disciplines spanning translational and clinical science. Simurx’s discovery and development approach is highly interdisciplinary and focuses on developing modular products that have a broad application spectrum.
Powerful CAR boosting technology.
The CTSR platform is a significant improvement in CAR therapies because it tackles the most substantial barrier in solid tumor cell therapy. The CTSR function not only activates CAR cells but also increases theirsurvival.
The signaling mechanism takes advantage of the highly immunosuppressive tumor environment; TGFβ levels are commonly elevated inside solid tumors.
CARs that otherwise flounder due to the tumor microenvironment can now survive, become activated and attach the tumor.
